[IgA nephropathy: what you have need to know in 2005]
- PMID: 15794304
[IgA nephropathy: what you have need to know in 2005]
Abstract
Although considered as a benign glomerulopathy, IgA nephropathy (IgAN) is now a well-known cause of end-stage renal disease (ESRD). Fifty percent of people suffering from IgAN developp renal insufficiency and 20 to 30% may reach ESRD after 20 to 25 years of evolution. ACEI is indicated to obtain a thigh control of blood pressure and to reduce proteinuria. Corticosteroids alone or in association with immunosuppressants are indicated for agressive, proliferative form of the disease or when there is an unfavorable outcome despite symptomatic treatment.
Similar articles
-
Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.J Nephrol. 2009 May-Jun;22(3):387-96. J Nephrol. 2009. PMID: 19557716
-
Monoamine oxidase inhibitors for IgA nephropathy.Med Hypotheses. 2001 Feb;56(2):225-6. doi: 10.1054/mehy.2000.1158. Med Hypotheses. 2001. PMID: 11425292
-
Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?Nephrol Dial Transplant. 2006 Dec;21(12):3550-4. doi: 10.1093/ndt/gfl506. Epub 2006 Sep 12. Nephrol Dial Transplant. 2006. PMID: 16968729
-
[Treatment of IgA nephropathy].Vnitr Lek. 2008 Mar;54(3):239-44. Vnitr Lek. 2008. PMID: 18522291 Review. Czech.
-
IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.Nat Clin Pract Nephrol. 2006 Jan;2(1):24-31. doi: 10.1038/ncpneph0055. Nat Clin Pract Nephrol. 2006. PMID: 16932386 Review.
Publication types
MeSH terms
LinkOut - more resources
Miscellaneous